Berger et al. evaluated the status of STING signaling in glioblastoma (GBM) tissues and investigated the immunomodulatory effects of the STING agonist ADU-S100 (synthetic cyclic dinucleotide -CDN) on the brain tumors microenvironment (TME) [48]. This evidence concerns the gene STING1 and brain neoplasm.